CDEK
← All organizations

Juno Therapeutics, Inc.

For profitContributed to NME

Also known as: Early Clinical Development | Juno | Juno Therapeutics, a Subsidiary of Celgene | Juno Therapeutics, Inc. | JunoTherapeutics, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 2

First clinical trial

Aug 1, 2015

Last known activity

Dec 29, 2020

Acquired by Celgene → Bristol-Myers Squibb on Jan 22, 2018

Timeline

2010s

  1. Aug 5, 2013

    Juno Therapeutics, Inc.— Founded

  2. May 12, 2015

    Stage Cell Therapeutics— Acquired

  3. Jun 2, 2015

    X-Body— Acquired

  4. Jan 11, 2016

    AbVitro— Acquired

  5. Jul 14, 2016

    Redox Therapies— Acquired

  6. Jan 22, 2018

    Celgene— Acquired By

  7. Jan 3, 2019

    Bristol-Myers Squibb— Now

Drugs by trial phase (19 distinct, 18 trials)

Indications

Studied for

Subsidiaries (4 direct, 4 total across the full acquisition tree)

Recent trials (25)

Details

Founded
Seattle, WA, US Aug 5, 2013
Last known activity
Dec 29, 2020